嵌合抗原受体修饰T细胞在肿瘤免疫治疗中的研究进展  

Research progress of chimeric antigen receptor-modified T lymphocytes in tumor immunotherapy

作　　者：赵媛媛[1] 孔宁[1] 王毅[1] 

机构地区：[1]吉林大学药学院,长春130021

出　　处：《世界复合医学》2015年第3期247-251,共5页World Journal of Complex Medicine

基　　金：吉林省科技厅青年基金(20130522011JH)

摘　　要：近年来,作为新型肿瘤免疫治疗技术,嵌合抗原受体(chimeric antigen receptor,CAR)T细胞在恶性肿瘤的治疗中取得了很好的成果,为部分晚期患者带来了康复的希望。CAR是利用基因工程技术将能够与肿瘤抗原结合的受体部分与胞内的信号转导部分相结合而形成的一种新型受体,经CAR修饰的T细胞可通过非MHC限制性的方式杀伤肿瘤细胞。本文就近年来CAR-T疗法的研究进展及其在恶性肿瘤临床治疗的应用进行综述。In recent years, as a novel tumor immunotherapy technology, chimeric antigen receptor（CAR）-modified T lymphocyte has made great achievements in immunotherapy technology for the treatment of malignant tumors, which has brought hope of recovery for part advanced patients. CAR is a kind of novel genetically engineered receptor which combines the antigen-binding region with the intracellular signal transduction region by genetic engineering technology. CAR- modified T Lymphocytes can kill tumor cells by means of non-MHC restriction. In this article, we highlight the applications of the CAR-T in the treatment of malignant tumor in recent years, and elaborate the development prospect in the future.

关 键 词：嵌合抗原受体 T细胞 肿瘤 免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]